奥曲肽治疗晚期肝细胞癌的临床观察

Clinical Study of Octreotide for Advanced Hepatocellular carcinoma

目的观察生长抑素类似物奥曲肽治疗晚期肝细胞癌的临床疗效。方法收集30例晚期肝细胞癌患者,治疗组16例,使用奥曲肽0.2mg,皮下注射,每12小时—次,用至病情有进展时停药;对照组14例,仅接受积极的支持治疗,每1个月进行1次疗效评价,并比较两组疗效。结果治疗组中无CR,1例PR,3例MR,5例SD,6例PD。总有效率为25%;对照组中无CR、PR、MR,3例SD,11例PD,总有效率为0%,两组有显著性差异(P<0.05)。治疗组中位生存期为7个月,对照组中位生存期为2.5个月,显著性差异(P<0.05);治疗组TTP为3.5个月,对照组为1.5个月,有显著性差异(P<0.05);奥曲肽治疗组较对照组患者的AFP水平明显下降(p<0.05);治疗组生活质量较对照组有明显提高,上消化道出血的发生率降低(P<0.05)。结论奥曲肽治疗晚期肝细胞癌能有效延长患者的生存期,提高生活质量。

Objective To evaluate the effect of octreotide for advanced hepatocellnlar carcinoma （HCC）. Methods Sixteen HCC patients were treated with octreotide at the dose of 0.2mg q12 h till the disease progresses, while fourteen patients were given the best supportive care only. Results There was significant difference in the response rate between two group （p〈0.05）. Patients treated with octreotide had an advantage in duration of survival time of 7 months vs 2.5 months, also an advantage in media aliment development time with 3.5 months vs 1.5 months in the control group and there was significant difference between the two groups （p〈 0.05）. Octreotide seems to improve the quality of life, decrease the happening of upper gastrointestinal hemorrhage. Conclusions Octreotide therapy seems to improve the quality of life and have a survival benefit in advanced hepatocellular carcinoma patients.